title: Dietary conjugated linoleic acid and body composition.
abstract: Conjugated linoleic acid (CLA) is a group of positional and geometric isomers of conjugated dienoic derivatives of linoleic acid. The major dietary source of CLA for humans is ruminant meats, such as beef and lamb, and dairy products, such as milk and cheese. The major isomer of CLA in natural food is cis-9,trans-11 (c9,t11). The commercial preparations contain approximately equal amounts of c9,t11 and trans-10,cis-12 (t10,c12) isomers. Studies have shown that CLA, specifically the t10,c12-isomer, can reduce fat tissue deposition and body lipid content but appears to induce insulin resistance and fatty liver and spleen in various animals. A few human studies suggest that CLA supplementation has no effect on body weight and could reduce body fat to a much lesser extent than in animals. To draw conclusions on this form of dietary supplementation and to ultimately make appropriate recommendations, further human studies are required. The postulated antiobesity mechanisms of CLA include decreased energy and food intakes, decreased lipogenesis, and increased energy expenditure, lipolysis, and fat oxidation. This review addresses recent studies of the effects of CLA on lipid metabolism, fat deposition, and body composition in both animals and humans as well as the mechanisms surrounding these effects.
authors.affiliation: School of Dietetics and Human Nutrition, McGill University, Ste-Anne-de-Bellevue, Quebec, Canada.
authors.forename: Yanwen
authors.initials: Y
authors.lastname: Wang
authors.forename: Peter J H
authors.initials: PJ
authors.lastname: Jones
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004042:Dietary Fats, Unsaturated / Q000008:administration & dosage*; D004734:Energy Metabolism / Q000187:drug effects; D006801:Humans; D007333:Insulin Resistance; D044243:Linoleic Acids, Conjugated / Q000008:administration & dosage* / Q000009:adverse effects; D008055:Lipids / Q000032:analysis / Q000096:biosynthesis; D010084:Oxidation-Reduction; D011506:Proteins / Q000032:analysis
chemical_list: D004042:Dietary Fats, Unsaturated; D044243:Linoleic Acids, Conjugated; D008055:Lipids; D011506:Proteins